Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
Baxter International Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders to be held on May 5, 2026. The proxy highlights governance and succession actions during a corporate transition, including the appointment of Andrew P. Hider as President and CEO in August 2025 and completion of strategic actions.
The company completed the sale of its Kidney Care business to Carlyle Group on January 31, 2025, generating approximately $3.3 billion of net after‑tax proceeds. The filing describes operational recovery from Hurricane Helene with North Cove IV production and inventory restored by May 2025. Proposals include election of nine directors, an advisory vote on 2025 executive pay, ratification of PricewaterhouseCoopers LLP, approval of an amended 2021 Incentive Plan and an amendment to reduce the Board minimum to five directors.
Baxter International senior vice president and chief accounting officer Anita A. Zielinski reported a routine tax-withholding transaction related to equity compensation. On March 6, 2026, 1,932 shares of common stock at $17.69 per share were forfeited to cover taxes from vested restricted stock units granted on March 6, 2025. After this withholding, she directly holds 46,281 Baxter shares.
Baxter International executive Maria Cecilia Soriano reported a routine tax-related share disposition. On March 6, 2026, 2,848 shares of common stock at $17.69 per share were forfeited to cover withholding taxes triggered by the delivery of shares from vested restricted stock units granted on March 6, 2024 and March 6, 2025. After this withholding transaction, she holds 75,045 Baxter shares directly.
Baxter International EVP and General Counsel David S. Rosenbloom had 6,620 shares of common stock withheld on March 6, 2026 to cover taxes arising from the settlement of vested restricted stock units granted on March 6, 2024 and March 6, 2025. These shares were not sold in the open market but forfeited back to the company for tax-withholding purposes at a value of $17.69 per share. Following this routine tax-withholding disposition, he directly holds 138,216 shares of Baxter common stock.
Baxter International executive Reazur Rasul reported a routine tax-related share disposition. On March 6, 2026, 12,674 shares of common stock were forfeited to cover withholding taxes triggered by the settlement of previously granted restricted stock units. After this withholding, Rasul directly holds 125,557 Baxter shares.
Baxter International EVP and CFO Joel T. Grade reported a routine tax-withholding share disposition. On March 6, 2026, 8,153 shares of common stock at $17.69 per share were forfeited to cover taxes triggered by the settlement of vested restricted stock units, not through an open-market sale. After this withholding, he directly holds 271,674 shares.
Hider Andrew P. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International President and CEO Andrew P. Hider reported awards of equity-based compensation. He received 488,506 stock options and 201,804 shares of common stock as a grant, both at a price of $0.00 per share. The stock grant consists of restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027, subject to vesting conditions under Baxter’s 2021 Incentive Plan. The options become exercisable on the same three-year schedule starting March 1, 2027.
Carlisle Cynthia reported acquisition or exercise transactions in this Form 4 filing.
Baxter International reported that Executive Vice President and CHRO Cynthia Carlisle received new equity awards. She was granted stock options for 43,103 shares, which become exercisable in three equal annual installments beginning on March 1, 2027. She also received 17,806 restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027, and an additional 11,871 restricted stock units scheduled to vest on February 27, 2029, all subject to vesting conditions under the company’s 2021 Incentive Plan.
Baxter International executive Reazur Rasul reported a tax-related share disposition. On March 2, 2026, 1,614 shares of common stock at $19.69 per share were forfeited to cover withholding taxes triggered by the settlement of vested restricted stock units granted on March 1, 2023. After this tax-withholding disposition, Rasul directly owned 138,231 Baxter shares.
Baxter International executive Maria Cecilia Soriano reported equity compensation changes involving common stock and options. On February 27, 2026, she acquired 23,742 shares of common stock at $0.00 per share as a grant, and received a stock option award covering 57,471 shares, also at $0.00 per share. These restricted stock units and options are scheduled to vest or become exercisable in three equal annual installments beginning on March 1, 2027, subject to the vesting requirements of Baxter’s 2021 Incentive Plan. On March 2, 2026, she disposed of 1,852 shares of common stock at $19.69 per share to cover taxes due on previously vested restricted stock units, leaving her with 77,894 common shares directly held.